OR WAIT null SECS
Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.
This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.
Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.
February 02, 2015
The 2016 White House Budget proposes a change to the data exclusivity period for biologics and the authority to influence drug pricing.
Tooling can be damaged by poor handling or problems in process design or material choice.
Ligand-binding assays are fundamental to characterizing biosimilars.
EMA is under pressure to exert even tighter standards on biosimilars being marketed in Europe.
Market forces may limit the success of CMOs.
Working with biological matrices and understanding the intended use are crucial.
New guidelines focused on the materials of construction in biologic therapy packaging will help vendors prepare comprehensive extractable and leachable testing strategies.
February 01, 2015
CMO executives share their opinions on where outsourcing is going and what is driving market change.
After launching a new mammalian cell platform, FUJIFILM Diosynth Biotechnologies U.S.A., has acquired fast-track vaccine manufacturing knowhow and a major presence in Texas’ emerging biocorridor with Kalon, its first acquisition.
January 29, 2015
Catalent will add potent containment for blending and granulation at its New Jersey manufacturing Center of Excellence.